In Brief: Rhone-Poulenc Rorer's Nasacort AQ
Rhone-Poulenc Rorer's Nasacort AQ: Water-based formulation of Nasacort for treatment of allergic rhinitis will be available in the end of June following May 20 FDA clearance, company announces. The CFC propellant-free aqueous microcrystalline suspension is indicated for once-daily use in children over age 12 and adults. Also, Nasacort was approved in children over age six, recommended at the same starting dose of 220 mcg per day given as two sprays in each nostril...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth